Femasys Leadership
Kathy Lee-Sepsick founded Femasys in February 2004. Ms. Lee-Sepsick has served as a senior executive in the medical technologies industry for nearly three decades, compiling a successful track record in growing emerging companies and corporate operating divisions. She holds over 100 patents globally for Femasys’ products and product candidates. Ms. Lee-Sepsick was instrumental in the various stages of product and company life cycles with strategic, operational, and executive responsibilities, at start-ups Novoste Corporation, developer of intravascular therapy solution and SaluMedica, biomaterial developer of artificial cartilage. At the onset of her career, Ms. Lee-Sepsick served in a product management role at Terumo Medical Corporation, where she was integral in the management of strategic partner, Boston Scientific Corporation. Ms. Lee-Sepsick also serves on the Board of Directors of Georgia Bio. Ms. Lee-Sepsick holds a BS in Biochemistry and an MBA from Rutgers University.
Daniel Currie has over 30 years of operational experience in the medical device industry, including assignments at early stage and large established companies. Mr. Currie worked closely with research and development teams, implemented and managed quality systems, spearheaded compliance and complaint handling systems at CIBA Vision Corporation. As head of Quality at Novoste Corporation, Mr. Currie oversaw and was directly involved in design and manufacturing controls, quality auditing (including FDA), evaluating and managing subcontractor operations, managing validation systems and performing product evaluations and testing. Mr. Currie holds a BBA in Economics from Georgia Southern University.
Dr. Lexy Kelley has over 14 years of successful leadership in clinical development and medical affairs, including global strategy development and operations for biopharmaceutical companies, such as UCB Pharma and Inhibitex, as well as serving as medical director at Novartis. Dr. Kelley served as Senior Medical Writer at Syneos Health, a biopharmaceutical company, and as Senior Director, Scientific Affairs at PRA International, a contract research organization. Dr. Kelley has a strong background in KOL outreach and networking, advisory board management and training of clinical staff and medical science liaisons. Dr. Kelley is well published with numerous publications and abstracts and was a pathology resident at Emory University. Dr Kelley holds a BA in Microbiology from Southern Illinois University and an MD from Southern Illinois University School of Medicine.
Tim Pruitt has over 30 years of engineering and management experience in the medical device industry, including machine design, process development, manufacturing engineering and operations for the manufacturing and distribution of medical devices, biologics and human tissue products for life sciences companies, such as Cryolife, Aderans Research Institute, Novoste and C.R. Bard. Mr. Pruitt is a certified lean six sigma black belt and has a proven track record of improving operational efficiency, creating a culture of quality, reducing COGs and improving gross margins. Mr. Pruitt is an inventor and has six issued patents. Mr. Pruitt holds a BS in Mechanical Engineering Technology from Southern Technical Institute (Kennesaw State University).
Gary Thompson has over 30 years of finance and management experience in medical device and pharmaceutical industries, including roles at C.R. Bard and Stiefel Labs. Mr. Thompson previously served in a unit within C.R. Bard as the head of finance responsible for all budgeting, strategic plans and reporting, and has assisted in structuring corporate strategic alliance agreements with financial models and support of contract negotiation. Mr. Thompson is a certified public accountant who started his career in public accounting with Deloitte Haskins and Sells. Mr. Thompson holds a BBA in Accounting from University of Notre Dame.
Mary An Merchant has been practicing intellectual property law for over 25 years. Ms. Merchant began her practice in Atlanta, Georgia, at the intellectual property boutique law firm, Jones & Askew, where she became a partner in 2000. Jones & Askew merged with Kilpatrick, Townsend & Stockton, where she was a partner for several years before establishing medical device/ pharmaceutical/ biotechnology intellectual practices as a partner with Troutman Sanders, Ballard Spahr, and Morris, Manning & Martin. Ms. Merchant has published many articles on intellectual property law and a book about the America Invents Act of 2011. Currently, Ms. Merchant serves as legal counsel to Femasys Inc. and Poly-Med, Inc. Ms. Merchant holds a BA in Biology from Randolph-Macon Woman’s College, a PhD in Virology from the University of Florida College of Medicine and a JD from University of Florida College of Law.
Todd Creech is a Partner with HealthQuest Capital, and has spent the last nine years as a healthcare CFO, helping build several successful companies to profitable exits. He currently serves as board member of HealthQuest portfolio companies Alcresta, BioIQ and Etairos and an observer for HealthChannels, Springbuk, and Venus Concept. He previously served as an observer for InMediata and Avedro (acquired by Glaukos). Previously, he served as CFO for ZS Pharma, Sarcode and Sirion Therapeutics. During his CFO tenure he has raised more than $500M in equity and debt, helping to build operations and companies that generated over $3.5B in exits. Earlier in his career, Mr. Creech did healthcare venture investing for Quintiles and worked with SRI International. He has also co-founded two companies; a spectroscopy platform spinout of Duke University (Centice) and a specialty pharmaceutical company (TLC Pharma). Mr. Creech holds BA in Finance and Accounting from Miami (Ohio) University and an MBA from Duke University.
Dr. Marcus has been a practicing Gynecologist/ Obstetrician for over 25 years. Dr. Marcus joined North Atlanta Women's Specialists when it was formed in 1994, and his special interests include management of high-risk pregnancies, minimally invasive gynecologic surgery, contraception, and menopause care. Dr. Marcus is board certified and a fellow of the American College of Obstetricians and Gynecologists. Dr. Marcus is a member of the American Association of Gynecologic Laparoscopists and the Society for Family Planning. In addition, Dr. Marcus is on the executive committee of the Atlanta Women’s Health Group and previously served as Chairman of Perinatal Services at Northside Hospital in Atlanta. Dr. Marcus holds a BS in physics from Dickinson College, and an MS in biomedical engineering and an MD from The George Washington University.
John Adams, Jr. has served as a member of our board of directors since April 2015. Mr. Adams has served as Chief Executive Officer of Adams Respiratory Therapeutics Inc. and served as its President since 2003. Adams Respiratory developed Mucinex and was subsequently acquired by Reckitt Benckiser for $2.3 billion. Mr. Adams founded and manages Legacy Capital Partners, LLC, an investment management and private equity firm focused on healthcare technology and pharmaceutical development. Mr. Adams holds a BA in Business from Austin College.
John Dyett has served as a member of our board of directors since January 2017. Mr. Dyett serves as the Co-CEO of Salem Partners, LLC and Salem Partners Wealth Management, LLC. Mr. Dyett helped raise several rounds of venture capital for Adams Respiratory Therapeutics, Inc. which was purchased for $2.3 billion by Reckitt Benckiser in 2008. Mr. Dyett helped launch ZS Pharma, Inc., a specialty pharmaceutical company. ZS Pharma, Inc. completed a successful initial public offering in June 2014 and was subsequently purchased by AstraZeneca for $2.7 billion. Mr. Dyett serves on the investment committee of Salem Partners Wealth Management. Mr. Dyett was also a banker with Gerard Klauer Mattison & Co., Inc. and Needham and Co., Inc. Mr. Dyett previously served on the board of directors of Sierra Total Return Fund. Mr. Dyett also serves on the board of directors of Medley Management and OncoNano Medicine. Mr. Dyett holds a BA in Government and Economics from Harvard College.
Charles Larsen has served as a member of our board of directors since October 2015. Mr. Larsen has over 35 years of operating and technical experience in the medical device industry. He co-founded Novoste Corporation in 1992 and The Innovation Factory in 1999, and through his role at The Innovation Factory, he co-founded additional companies including medical device companies such as Acufocus, Inc., AqueSys Inc., Halscion, Inc., Neuronetics, Inc. and Sebacia, Inc. He holds over 30 issued U.S. and international patents on medical devices. Before joining Novoste, Mr. Larsen held positions with Novoste Puerto Rico, Cordis Corporation, Key Pharmaceuticals and Parke-Davis/Warner Lambert in executive, senior engineering and project management roles. Mr. Larsen also serves on the Board of Directors of Acufocus, CardioFocus, Intuity Medical Inc., and Torax Medical, Inc. Mr. Larsen holds a BS in Mechanical Engineering from the New Jersey Institute of Technology.
Edward Uzialko, Jr. has served as a member of our board of directors since August 2005. Mr. Uzialko was the founder and Chief Executive Officer of Lynk Systems, Inc. from 1991 until it was acquired by Royal Bank of Scotland in 2004. Lynk provided electronic payment, cash dispensing and e-commerce services. Lynk was a full-service Value Added Reseller offering ongoing support for hardware, software, and project development for Hewlett Packard, Motorola, Microsoft and various other technological products. Mr. Uzialko has also served as the owner and Chief Executive Officer of Mainstream Merchant Services, a credit card processing firm, since 2007. Mr. Uzialko attended the Florida Institute of Technology from 1969 to 1973.
William Witte has served as a member of our board of directors since January 2017. Mr. Witte is President of Salem Partners Wealth Management, LLC and has over 28 years of experience in the financial and capital markets. Prior to joining the Salem Partners, Mr. Witte was the Chief Investment Officer for Caruso Affiliated, where he was in charge of all capital decisions for the company, including strategic and tactical asset allocation, budgeting, forecasting, tax planning, and manager due diligence, as well as development of their multi-billion dollar real estate portfolio. Mr. Witte has worked in investment banking, corporate banking, private banking, and investment management for UBS, Bankers Trust Company, and Shearson Lehman Brothers. Mr. Witte also serves on the Board of Directors for Front Porch Communities and Services. Mr. Witte holds a BS in Petroleum Engineering from Stanford University.